Investigational Drug Information for Delamanid

What is the drug development status for Delamanid?

Delamanid is an investigational drug.

There have been 24 clinical trials for Delamanid. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1^st 2020.

The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Multidrug-Resistant, and Tuberculosis, Pulmonary. The leading clinical trial sponsors are Otsuka Pharmaceutical Development & Commercialization, Inc., National Institute of Allergy and Infectious Diseases (NIAID), and Harvard Medical School.

There are nine US patents protecting this investigational drug and two hundred and eighty-nine international patents.

Summary for Delamanid

US Patents	9
International Patents	289
US Patent Applications	26
WIPO Patent Applications	9
Japanese Patent Applications	0
Clinical Trial Progress	Phase 3 (2020-07-01)
Vendors	49

Recent Clinical Trials for Delamanid

Title	Sponsor	Phase
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB	Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic	Phase 2
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB	Harvard School of Public Health (HSPH)	Phase 2
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB	University of California, Los Angeles	Phase 2

See all Delamanid clinical trials

Clinical Trial Summary for Delamanid

Top disease conditions for Delamanid

Top clinical trial sponsors for Delamanid

See all Delamanid clinical trials

US Patents for Delamanid

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Delamanid		Nitroimidazooxazine and nitroimidazooxazole analogues and their uses	Global Alliance for TB Drug Development (New York, NY)
Delamanid		Pharmaceutical composition achieving excellent absorbency of pharmacologically active substance	Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Delamanid		Antituberculous composition comprising oxazole compounds	Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Delamanid		Nitroimidazooxazines and their uses in anti-tubercular therapy	Global Alliance for TB Drug Development (New York, NY)
Delamanid		Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same	UNIVERSITY OF NOTRE DAME DU LAC (Notre Dame, IN)
Delamanid		Combination therapy to treat Mycobacterium diseases	SPERO TRINEM, INC. (Cambridge, MA)
Delamanid		6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles and a process for the preparation thereof	COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (New Delhi, IN)

International Patents for Delamanid

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Delamanid	China	CN107406386	2035-03-27
Delamanid	Eurasian Patent Organization	EA201792154	2035-03-27
Delamanid	European Patent Office	EP3275862	2035-03-27
Delamanid	Japan	JP6776226	2035-03-27
Delamanid	Japan	JPWO2016158737	2035-03-27
Delamanid	South Korea	KR20170129898	2035-03-27
Delamanid	Lithuania	LT3275862	2035-03-27